Bacteriocins as potential anticancer agents

Frontiers in Pharmacology

Volumn 6, Issue NOV, 2015, Pages

  Kaur, Sumanpreet ^a   Kaur, Sukhraj ^a  

^a GURU NANAK DEV UNIVERSITY   (India)

Author keywords

Anticancer; Bacteriocin; Cancer; Colicin; Cytotoxicity; Microcin; Nisin; Pediocin

Indexed keywords

BACTERIOCIN; BOVICIN; COLICIN; LANTIBIOTIC; MICROCIN; MICROCIN E492; NISIN; PEDIOCIN; PLANTARICIN A; PYOCIN; SMEGMATOCIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CLASSIFICATION; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SELECTIVITY; HUMAN; IC50; IN VITRO STUDY; NONHUMAN; REVIEW;

EID: 84949772516     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00272     Document Type: Review

References (99)

1. Abdi-Ali, A., Worobec, E. A., Deezagi, A., and Malekzadeh, F. (2004). Cytotoxic effects of pyocin S2 produced by Pseudomonas aeruginosa on the growth of three human cell lines. Can. J. Microbiol. 50, 375-381. doi: 10.1139/w04-019
2. Beaulieu, L. (2004). Production, Purification et Caracterisation de la Pediocine PA-1 Naturelle et de ses Formes Recombiantes: Contribution a la Mise en Evidence d'une Nouvelle Activite Biologique. Quebec: Universite Laval.
3. Begde, D., Bundale, S., Mashitha, P., Rudra, J., Nashikkar, N., and Upadhyay, A. (2011). Immunomodulatory efficacy of nisin-a bacterial lantibiotic peptide. J. Pept. Sci. 17, 438-444. doi: 10.1002/psc.1341
4. Belkum, M. J., Martin-Visscher, L. A., and Vederas, J. C. (2011). Structure and genetics of circular bacteriocins. Trends Microbiol. 19, 411-418. doi: 10.1016/j.tim.2011.04.004
5. Bhunia, A. K., Johnson, M. C., Ray, B., and Belden, E. L. (1990). Antigenic property of Pediocin AcH produced by Pediococcus acidilactici H. J. Appl. Bacteriol. 69, 211-215. doi: 10.1111/j.1365-2672.1990.tb01511.x
6. Bowman, C. M., Sidikaro, J., and Nomura, M. (1971). Specific inactivation of ribosomes by colicin E3 in vitro and mechanism of immunity in colicinogenic cells. Nat. New Biol. 234, 133-137. doi: 10.1038/newbio234133a0
7. Brader, P., Stritzker, J., Riedl, C. T., Zanzonico, P., Cai, S., Burnazi, E. M., et al. (2008). Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging. Clin. Cancer Res. 14, 2295-2302. doi: 10.1158/1078-0432.CCR-07-4254
8. Braun, V., Pilsl, H., and Gross, P. (1994). Colicins: structures, modes of action, transfer through membranes, and evolution. Arch. Microbiol. 161, 199-206. doi: 10.1007/BF00248693
9. Carolissen-Mackay, V., Arendse, G., and Hastings, J. (1997). Purification of bacteriocins of lactic acid bacteria: problems and pointers. Int. J. Food Microbiol. 34, 1-16. doi: 10.1016/S0168-1605(96)01167-1
10. Chan, S. C., Hui, L., and Chen, H. M. (1998a). Enhancement of the cytolytic effect of anti-bacterial cecropin by the microvilli of cancer cells. Anticancer. Res. 18, 4467-4474.
11. Chan, S. C., Yau, W. L., Wang, W., Smith, D. K., Sheu, F. S., and Chen, H. M. (1998b). Microscopic observations of the different morphological changes caused by anti-bacterial peptides on Klebsiella pneumoniae and HL-60 leukemia cells. J. Pept. Sci. 4, 413-425.
12. Chaudhary, J., and Munshi, M. (1995). Scanning electron microscopic analysis of breast aspirates. Cytopathology 6, 162-167. doi: 10.1111/j.1365-2303.1995.tb00469.x
13. Chumchalova, J., and Smarda, J. (2003). Human tumor cells are selectively inhibited by colicins. Folia Microbiol. (Praha). 48, 111-115. doi: 10.1007/BF02931286
14. Cornut, G., Fortin, C., and Soulieres, D. (2008). Antineoplastic properties of bacteriocins: revisiting potential active agents. Am. J. Clin. Oncol. 31, 344-404. doi: 10.1097/COC.0b013e31815e456d
15. Cotter, P. D., Hill, C., and Ross, R. P. (2005). Bacteriocins: developing innate immunity for food. Nat. Rev. Microbiol. 3, 777-788. doi: 10.1038/nrmicro1273
16. Cramer, W. A., Cohen, F. S., Merrill, A. R., and Song, H. Y. (1990). Structure and dynamics of the colicin E1 channel. Mol. Microbiol. 4, 519-526. doi: 10.1111/j.1365-2958.1990.tb00619.x
17. Cursino, L., Smarda, J., Chartone-Souza, E., and Nascimento, A. M. A. (2002). Recent updated aspects of colicins of Enterobacteriaceae. Braz. J. Microbiol. 33, 185-195. doi: 10.1590/S1517-83822002000300001
18. Daeschel, A., McKenney, M. C., and McDonald, L. C. (1990). Bactericidal activity of Lactobacillus plantarum C-11. Food Microbiol. 7, 91-99. doi: 10.1016/0740-0020(90)90014-9
19. Deegan, L. H., Cotter P. D., and Hill C. And Ross, P. (2006). Bacteriocins: biological tools for bio-preservation and shelf-life extension. Int. Dairy J. 16, 1058-1071. doi: 10.1016/j.idairyj.2005.10.026
20. Diep, D. B., Håvarstein, L. S., and Nes, I. F. (1996). Characterization of the locus responsible for the bacteriocin production in Lactobacillus plantarum C11. J. Bacteriol. 178, 4472-4483.
21. Dobrzynska, I., Szachowicz-Petelska, B., Figaszewski, Z., and Sulkowski, S. (2005). Changes in electric charge and phospholipid composition in human colorectal cancer cells. Mol. Cell Biochem. 276, 113-119. doi: 10.1007/s11010-005-3557-3
22. Drider, D., Fimland, G., Hechard, Y., McMullen, L. M., and Prevost, H. (2006). The continuing story of class IIa bacteriocins. Microbiol. Mol. Biol. Rev. 70, 564-582. doi: 10.1128/MMBR.00016-05
23. Farkas-Himsley, H., and Cheung, R. (1976). Bacterial proteinaceous products (bacteriocins) as cytotoxic agents of neoplasia. Cancer Res. 36, 3561-3567.
24. FDA. (1988). Federal Register, Nisin preparation: affirmation of GRAS status as a direct human food ingredient. Fed. Reg. 53, 11247-11251.
25. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., et al. (2013). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer.
26. Fimland, G., Johnsen, L., Dalhus, B., and Nissen-Meyer, J. (2005). Pediocin-like antimicrobial peptides (class IIa bacteriocins) and their immunity proteins: biosynthesis, structure, and mode of action. J. Pept. Sci. 11, 688-696. doi: 10.1002/psc.699
27. Fuska, J., Fuskova, A., Smarda, J., and Mach, J. (1978). Effect of colicin E3 on leukemia cells P388 in vitro. Experientia 35, 406-407. doi: 10.1007/BF01964380
28. Gaspar, D., Veiga, A. S., and Castanho, M. A. (2013). From antimicrobial to anticancer peptides: a review. Front. Microbiol. 4:294. doi: 10.3389/fmicb.2013.00294
29. Gratia, A. (1925). Sur un remarquable example d'antagonisme entre deux souches de colibacille. Compt. Rend. Soc. Biol. 93, 1040-1042.
30. Gratia, A., and Fredericq, P. (1946). Diversite' des souches antibiotiques de E. coli et e'tendue variable de leur champs d'action. C. R. Soc. Biol. (Paris). 140, 1032-1033.
31. Hanahan, D., and Weinberg, R. A. (2011). The hallmarks of cancer: the next Generation. Cell 144, 646-673. doi: 10.1016/j.cell.2011.02.013
32. Hansen, J. N., and Liu, W. (1990). Some chemical and physical properties of nisin, a small-protein antibiotic produced by Lactococcus lactis. Appl. Environ. Microbiol. 56, 2551-2558.
33. Hetz, C., Bono, M. R., Barros, L. F., and Lagos, R. (2002). Microcin E492, a channel-forming bacteriocin from Klebsiella pneumoniae, induces apoptosis in some human cell lines. Proc. Natl. Acad. Sci. U.S.A. 99, 2696-2701. doi: 10.1073/pnas.052709699
34. Hoskin, D. W., and Ramamoorthy, A. (2008). Studies on anticancer activities of antimicrobial peptides. Biochem. Biophys. Acta 1778, 357-375. doi: 10.1016/j.bbamem.2007.11.008
35. Imajoh, S., Ohno-Iwashita, Y., and Imahori, K. (1982). The receptor for colicin E3. Isolation and some properties. J. Biol. Chem. 257, 6481-6487.
36. Jack, R. W., Tagg J. R., and Ray, B. (1994). Bacteriocins of Gram-positive bacteria. Microbiol. Rev. 59, 171-200.
37. Jacob, F. (1954). Biosynthèse induite et mode d'action d'une pyocin, antibiotique de Pseudomonas pyocyanea. Annals Inst. Pasteur. 86, 149-160.
38. James, R., Kleanthous, C., and Moore, G. R. (1996). The biology of E colicins: paradigms and paradoxes. Microbiology 142, 1569-1580. doi: 10.1099/13500872-142-7-1569
39. Jennsen, H., Hamill, P., and Hancock, R. E. W. (2006). Peptide antimicrobial agents. Clin. Microbiol. Rev. 19, 491-511. doi: 10.1128/CMR.00056-05
40. Joo, N. E., Ritchie, K., Kamarajan, P., Miao, D., and Kapila, Y. I. (2012). Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC1. Cancer Med. 1, 295-305. doi: 10.1002/cam4.35
41. Kageyama, M., and Egami, F. (1962). On the purification and some properties of a pyocin, a bacteriocin produced by Pseudomonas aeruginosa. Life Sci. 9, 471-476. doi: 10.1016/0024-3205(62)90055-3
42. Kamarajan, P., Hayami, H., Matte, B., Liu, Y., Danciu, T., Ramamoorthy, A., et al. (2015). Nisin ZP, a bacteriocin and food preservative, inhibits head and neck cancer tumorigenesis and prolongs survival. PLoS ONE 10:e0131008. doi: 10.1371/journal.pone.0131008
43. Kawai, Y., Kemperman, R., Kok, J., and Saito, T. (2004). The circular bacteriocins: gassericin A and circularin A. Curr. Protein Pept. Sci. 5, 393-398. doi: 10.2174/1389203043379549
44. Klaenhammer, T. R., Fremaux, C., Ahn, C., and Milton. K. (1993). "Molecular biology of bacteriocins produced by Lactobacillus, "in Bacteriocins of Lactic Acid Bacteria, eds D. G. Hoover and L. R. Steenson. (New York: Academic press Inc.), 151-180.
45. Kruis, W. (2004). Review article: antibiotics and probiotics in inflammatory bowel disease. Aliment Pharmacol. Ther. 20, 75-78. doi: 10.1111/j.1365-2036.2004.02051.x
46. Kumar, B., Balgir, P. P., Kaur, B., Mittu B., and Chauhan, A. (2012). In vitro cytotoxicity of native and rec-pediocin cp2 against cancer cell lines: a comparative study. Open Access Sci. Rep. 1, 316-321. doi: 10.4172/2153-2435.1000183
47. Kumar, B., Kaur, B., Balgir, P. P., and Garg, N. (2011). Cloning and expression of bacteriocins of Pediococcus spp. Arch. Clin. Microbiol. 2, 1-18.
48. Lagos, R., Tello, M., Mercado, G., Garcia, V., and Monasterio, O. (2009). Antibacterial and antitumorigenic properties of microcin E492, a pore-forming bacteriocin. Curr. Pharm. Biotechnol. 10, 74-85. doi: 10.2174/138920109787048643
49. Lagos, R., Wilkens, M., Vergara, C., Cecchi, X., and Monasterio, O. (1993). Microcin E492 forms ion channels in phospholipid bilayer membranes. FEBS Lett. 321, 145-148. doi: 10.1016/0014-5793(93)80096-D
50. Lakey, J. H., and Slatin, S. L. (2001). Pore forming colicins and their relatives. Curr. Top. Microbiol. Immunol. 257, 131-161. doi: 10.1007/978-3-642-56508-3_7
51. Lohans, C. T., and Vederas, J. C. (2012). Development of Class IIa bacteriocins as therapeutic agents. Int. J. Microbiol. 2012, 13. doi: 10.1155/2012/386410
52. Lorenzo, V. (1984). Isolation and characterization of microcin E492 from Klebsiella pneumoniae. Arch. Microbiol. 139, 72-75. doi: 10.1007/BF00692715
53. Lorenzo, V., and Pugsley, A. P. (1985). Microcin E492, a low-molecular-weight peptide antibiotic which causes depolarization of the Escherichia coli cytoplasmic membrane. Antimicrob. Agents Chemother. 27, 666-669. doi: 10.1128/AAC.27.4.666
54. Maher, S., and McClean, S. (2006). Investigation of the cytotoxicity of eukaryotic and prokaryotic antimicrobial peptides in intestinal epithelial cells in vitro. Biochem. Pharmacol. 71, 1289-1298. doi: 10.1016/j.bcp.2006.01.012
55. Mantovani, H. C., Hu, H., Worobo, R. W., and Russell, J. B. (2002). Bovicin HC5, a bacteriocin from Streptococcus bovis HC5. Microbiology 148, 3347-3352. doi: 10.1099/00221287-148-11-3347
56. Martín, R., Escobedo, S., Martín, C., Crespo, A., Quiros, L. M., and Suarez, J. E. (2015). surface glycosaminoglycans protect eukaryotic cells against membrane-driven peptide bacteriocins. Antimicrob. Agents Chemother. 59, 677-681. doi: 10.1128/AAC.04427-14
57. Michel-Briand, Y., and Baysse, C. (2002). The pyocins of Pseudomonas aeruginosa. Biochimie 84, 499-510. doi: 10.1016/S0300-9084(02)01422-0
58. Nes, I. F., and Holo, H. (2000). Class II antimicrobial peptides from lactic acid bacteria. Biopolymers (Pept. Sci.). 55, 50-61.
59. Nissen-Meyer, J., Larsen, A. G., Sletten, K., Daeschel, M., and Nes, I. (1993). Purification and characterization of plantaricin A, a Lactobacillus plantarum bacteriocin whose activity depends on the action of two peptides. J. Gen. Microbiol. 139, 1973-1978. doi: 10.1099/00221287-139-9-1973
60. Oppegård, C., Rogne, P., Kristiansen, P. E., and Nissen-Meyer, J. (2010). Structure analysis of the two-peptide bacteriocin lactococcin G by introducing D-amino acid residues. Microbiology 156, 1883-1889. doi: 10.1099/mic.0.038430-0
61. Paiva, A. D., Breukink, E., and Mantovani, H. C. (2011). Role of lipid II and membrane thickness in the mechanism of action of the lantibiotic bovicin HC5. Antimicrob. Agents Chemother. 55, 5284-5293. doi: 10.1128/AAC.00638-11
62. Paiva, A. D., de Oliveira, M. D., de Paula, S. O., Baracat-Pereira, M. C., Breukink, E., and Mantovani, H. C. (2012). Toxicity of bovicin HC5 against mammalian cell lines and the role of cholesterol in bacteriocin activity. Microbiology 158, 2851-2858. doi: 10.1099/mic.0.062190-0
63. Papagianni, M. (2003). Ribosomally synthesized peptides with antimicrobial properties: biosynthesis, structure, function, and applications. Biotechnol. Adv. 21, 465-499. doi: 10.1016/S0734-9750(03)00077-6
64. Papagianni, M., and Anastasiadou, S. (2009). Pediocins: the bacteriocins of Pediococci. Sources, production, properties and applications. Microb. Cell Fact. 8, 1-16. doi: 10.1186/1475-2859-8-3
65. Preet, S., Bharati, S., Panjeta, A., Tewari, R., and Rishi, P. (2015). Effect of nisin and doxorubicin on DMBA-induced skin carcinogenesis-a possible adjunct therapy. Tumor. Biol. doi: 10.1007/s13277-015-3571-3
66. Raguz, S., and Yagüe, E. (2008). Resistance to chemotherapy: new treatments and novel insights into an old problem. Brit. J. Cancer 99, 387-391. doi: 10.1038/sj.bjc.6604510
67. Rembacken, B. J., Snelling, A. M., Hawkey, P. M., Chalmers, D. M., and Axon, A. T. (1999). Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354, 635-639. doi: 10.1016/S0140-6736(98)06343-0
68. Rich, F. J., Kuhn, S., Hyde, E. J., Harper, J. L., Ronchese, F., and Kirman, J. R. (2012). Induction of T cell responses and recruitment of an inflammatory dendritic cell subset following tumor immunotherapy with Mycobacterium smegmatis. Cancer Immunol. Immunother. 12, 2333-2342. doi: 10.1007/s00262-012-1291-8
69. Riedl, S., Rinner, B., Asslaber, M., Schaider, H., Walzer, S., Novak, A., et al. (2011). In search of a novel target-Phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochim. Biophys. Acta 1808, 2638-2645. doi: 10.1016/j.bbamem.2011.07.026
70. Rodríguez, J. M., Martínez, M. I., Horn, N., and Dodd, H. M. (2003). Heterologous production of bacteriocins by lactic acid bacteria. Int. J. Food Microbiol. 80, 101-116. doi: 10.1016/S0168-1605(02)00153-8
71. Ruhr, E., and Sahl, H. G. (1985). Mode of action of the peptide antibiotic nisin and influence on the membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles. Antimicrob. Agents Chemother. 25, 841-845. doi: 10.1128/AAC.27.5.841
72. Sahl, H. G., and Bierbaum, G. (1998). Lantibiotics: biosynthesis and biological activities of uniquely modified peptides from gram-positive bacteria. Ann. Rev. Microbiol. 52, 41-79. doi: 10.1146/annurev.micro.52.1.41
73. Sahl, H. G., Kordel, M., and Benz, R. (1987). Voltage-dependent depolarization of bacterial membranes and artificial lipid bilayers by the peptide antibiotic nisin. Arch. Microbiol. 149, 120-124. doi: 10.1007/BF00425076
74. Saito, H., and Watanabe, T. (1979). Effect of a bacteriocin produced by Mycobacterium smegmatis on growth of cultured tumor and normal cells. Cancer Res. 39, 5114-5117.
75. Saito, H., and Watanabe, T. (1981). Effects of a bacteriocin from Mycobacterium smegmatis on BALB/3T3 and Simian Virus 40-Transformed BALB/c mouse cells. Microbiol. Immunol. 25, 13-22. doi: 10.1111/j.1348-0421.1981.tb00002.x
76. Saito, H., Watanabe, T., and Tomioka, H. (1979). Purification, properties and cytotoxic effect of a bacteriocin from Mycobacterium smegmatis. Antimicrob. Agents Chemother. 15, 504-509. doi: 10.1128/AAC.15.4.504
77. Sand, S. L., Haug, T. M., Nissen-Meyer, J., and Sand, O. (2007). The bacterial peptide pheromone plantaricin A permeabilizes cancerous, but not normal, rat pituitary cells and differentiates between the outer and inner membrane leaflet. J. Membrane Biol. 216, 61-71. doi: 10.1007/s00232-007-9030-3
78. Sand, S. L., Nissen-Meyer, J., Sand, O., and Haug, T. M. (2013). Plantaricin A, a cationic peptide produced by Lactobacillus plantarum, permeabilizes eukaryotic cell membranes by a mechanism dependent on negative surface charge linked to glycosylated membrane proteins. Biochim. Biophys. Acta 1828, 249-259. doi: 10.1016/j.bbamem.2012.11.001
79. Sand, S. L., Oppegård, C., Ohara, S., Iijima, T., Naderi, S., Blomhoff, H. K., et al. (2010). Plantaricin A, a peptide pheromone produced by Lactobacillus plantarum, permeabilizes the cell membrane of both normal and cancerous lymphocytes and neuronal cells. Peptides 31, 1237-1244. doi: 10.1016/j.peptides.2010.04.010
80. Schweizer, F. (2009). Cationic amphiphilic peptides with cancer-selective toxicity. Eur. J. Pharmacol. 625, 190-194. doi: 10.1016/j.ejphar.2009.08.043
81. Shea, E. F., O'Connor, P. M., Cotter, P. D., Ross, R., and Hill, C. (2010). Synthesis of trypsin-resistant variants of the Listeria bacteriocin salivaricin P. Appl. Environ. Microbiol. 76, 5356-5362. doi: 10.1128/AEM.00523-10
82. Smarda, J., Fialova, M., and Smarda, J. Jr. (2001). Cytotoxic effects of colicins E1 and E3 on v-myb-transformed chicken monoblasts. Folia Biol. 47, 11-13.
83. Smarda, J., Obdržálek, V., Táborskỳ, I., and Mach, J. (1978). The cytotoxic and cytocidal effect of colicin E3 on mammalian tissue cells. Folia Microbiol. 23, 272-277. doi: 10.1007/BF02876680
84. Smarda, J., and Oravec, C. (1989). Cytocidal effect of bacteriocin on lymphoma cells. Akt. Klin. Onkol. 21, 209-212.
85. Smarda, J., and Smajs, D. (1998). Colicins-exocellular lethal proteins of Escherichia coli. Folia Microbiol (Praha). 43, 563-582. doi: 10.1007/BF02816372
86. Sok, M., Sentjurc, M., and Schara, M. (1999). Membrane fluidity characteristics of human lung cancer. Cancer Lett. 139, 215-220. doi: 10.1016/S0304-3835(99)00044-0
87. Suzuki, H. (1978). Colicin E3 inhibits rabbit globin synthesis. FEBS Lett. 89, 121-125. doi: 10.1016/0014-5793(78)80536-5
88. Tomita, K., Ogawa, T., Uozumi, T., Watanabe, K., and Masaki, H. (2000). A cytotoxic ribonuclease which specifically cleaves four isoaccepting arginine tRNAs at their anti-codon loops. Proc. Natl. Acad. Sci. U.S.A. 97, 8278-8283. doi: 10.1073/pnas.140213797
89. Turner, D. L., Brennan, L., Meyer, H. E., Lohaus, C., Siethoff, C., Costa, H. S., et al. (1999). Solution structure of plantaricin C, a novel lantibiotic. Eur. J. Biochem. 264, 833-839. doi: 10.1046/j.1432-1327.1999.00674.x
90. Turnowsky, F., Drews, J., Eich, F., and Hogenauer, G. (1973). In vitro inactivation of ascites ribosomes by colicin E3. Biochem. Biophys. Res. Commun. 52, 327-334. doi: 10.1016/0006-291X(73)90991-1
91. Utsugi, T., Schroit, A. J., Connor, J., Bucana, C. D., and Fidler, I. J. (1991). Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 51, 3062-3066.
92. Villarante, K. I., Elegado, F. B., Iwatani, S., Zendo, T., Sonomoto, K., and de Guzman, E. E. (2011). Purification and characterization and in vitro cytotoxicity of the bacteriocin from Pediococcus acidilactici K2a2-3 against human colon adenocarcinoma (HT29) and human cervical carcinoma (HeLa) cells. World J. Microbiol. Biotechnol. 27, 975-980. doi: 10.1007/s11274-010-0541-1
93. Watanabe T., and Saito, H. (1980). Cytotoxicity of pyocin S2 to tumor and normal cells and its interaction with cell surfaces. Biochim. Biophys. Acta 633, 77-86. doi: 10.1016/0304-4165(80)90039-2
94. Wiedemann, I., Breukink, E., van Kraaij, C., Kuipers, O. P., Bierbaum, G., de Kruijff, B., et al. (2001). Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J. Biol. Chem. 276, 1772-1779. doi: 10.1074/jbc. M006770200
95. World Health Organization. (1969). Specifications for the Identity and Purity of Food Additives and Their Toxicological Evaluation: Some Antibiotics. Twelfth Report of Joint FAO/WHO Expert Committee on Food Additives. WHO Technical Report No. 430. Geneva, pp. 33-35.
96. Young, S. L., Murphy, M., Zhu, W. Z., Harnden, P., Donnel, M. A., James, K., et al. (2004). Cytokine-modified Mycobacterium smegmatis as a novel anticancer immunotherapy. Int. J. Cancer 112, 653-660. doi: 10.1002/ijc.20442
97. Zacharof, M. P., and Lovitt R. W. (2012). Bacteriocins produced by lactic acid bacteria. APCBEE Procedia 2, 50-56. doi: 10.1016/j.apcbee.2012.06.010
98. Zhao, H., Tuominen, E. K. J., and Kinnunen, P. K. J. (2004). Formation of amyloid fibers triggered by phosphatidylserine containing membranes. Biochemistry 43, 10302-10307. doi: 10.1021/bi049002c
99. Zhao, H., Sood, R., Jutila, A., Bose, S., Fimland, G., Nissen-Meyer, J., et al. (2006). Interaction of the antimicrobial peptide pheromone plantaricin A with model membranes: implications for a novel mechanism of action. Biochim. Biophys. Acta 1758, 1461-1474. doi: 10.1016/j.bbamem.2006.03.037